Beam Therapeutics (BEAM) Enterprise Value (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Enterprise Value data on file, last reported at -$1.2 billion in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$1.2 billion, up 0.68% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.2 billion (up 0.68% YoY), and the FY2025 annual result was -$1.2 billion, down 46.37% from the prior year.
• Enterprise Value climbed to -$1.2 billion in Q1 2026 per BEAM's latest filing, from -$1.2 billion in the prior quarter.
• Over five years, Enterprise Value peaked at -$156.5 million in Q3 2022 and troughed at -$1.2 billion in Q4 2025.
• A 5-year average of -$936.2 million and a median of -$1.1 billion in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value surged 83.23% in 2022, then tumbled 548.81% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$1.1 billion in 2022, then slipped by 10.36% to -$1.2 billion in 2023, then climbed by 28.5% to -$850.7 million in 2024, then plunged by 46.37% to -$1.2 billion in 2025, then climbed by 2.69% to -$1.2 billion in 2026.
• Business Quant data shows BEAM's Enterprise Value at -$1.2 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.1 billion in Q3 2025.